Heart Outcomes Prevention and Evaluation 4

PHASE4CompletedINTERVENTIONAL
Enrollment

1,438

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

February 28, 2019

Study Completion Date

February 28, 2019

Conditions
HypertensionCardiovascular Disease
Interventions
OTHER

Intervention

In intervention communities, management plans will be developed by the NPHW for all enrolled participants. The NPHWs will educate participants about CVD, HT treatment, lifestyle modifications and initiate therapy according to the modified WHO CVD risk-management algorithm, including referral of high-risk patients to physicians and safety monitoring where appropriate. Participants in intervention communities will have support from family or friends (treatment supporters) and will receive educational materials and treatment reminders using text-messaging, email, and printed materials, as appropriate for the participant and the community setting. Evidence-based CV medications will be made available to the NPHWs and supervising physicians for participant treatment.

OTHER

Usual Care

At initial screening, eligible participants will be provided with a brief information booklet/leaflet (customized to the community or region) regarding lifestyle modification and be advised to see their usual physician for care that is considered appropriate. No structured interventions will be employed.

Trial Locations (4)

47000

UniversitiTeknologi MARA (UiTM), Sungai Buloh

V5A 1S6

Simon Fraser University, Burnaby

L8L 2X2

Population Health Research Institute, Hamilton

Unknown

FOSCAL, Floridablanca

Sponsors
All Listed Sponsors
collaborator

Population Health Research Institute

OTHER

collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Grand Challenges Canada

OTHER

collaborator

Global Alliance for Chronic Diseases (GACD)

OTHER

lead

Hamilton Health Sciences Corporation

OTHER

NCT01826019 - Heart Outcomes Prevention and Evaluation 4 | Biotech Hunter | Biotech Hunter